Drugs / Alkaline Phosphatase
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00457613 | Nov 2004 → Mar 2006 | infectious disease | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00430859 | Sep 2004 → Mar 2006 | infectious disease with sepsis, multiple organ dysfunction syndrome | AM-Pharma | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alkaline Phosphatase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00430859 ↗ |
| Action | Inhibit | “In severe sepsis and septic shock, infusion of AP inhibits the upregulation of renal inducible NO synthase, leading to subsequent reduced NO metabolite production, and...” PMID 19114895 ↗ Feb 2009 |
| Modality | Protein / enzyme biologic | “The relatively short elimination half-life necessitated a loading dose to achieve stable enzyme levels.” PMID 19048243 ↗ Dec 2008 |
| Route | Intravenous | “Intravenous over a period of 24 hours” NCT00430859 ↗ |